FedEx Freight Holding shares have dropped about 40% since its June spinoff, trading above sector averages despite challenges. The first standalone quarter included $80 million in separation costs and the absence of a prior $33 million facility-sale gain, which obscured true business performance. Management aims to grow margins to 15% and generate over $1 billion in annual free cash flow, but risks related to execution and leverage remain uncertain. Investors are advised to wait for the October 9 earnings report before making investment decisions due to current valuation and transition risks.
FedEx Freight Holding faces uncertainty ahead of its October 9 earnings report. For readers following the Industrials sector, here is Pluang's market snapshot as of Sep 25, 2026 18:02 WIB: out of 93 priced US Industrials stocks, 70 rose and 20 fell today. Notable movers include SMX at USD 9.20 (+5.14%), Expeditors International (EXPD) at USD 192.15 (+4.62%), and AGCO at USD 121.58 (+4.62%), with varying typical hold times and order activity on Pluang.
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...
